ANNEXON INC
ANNXNASDAQTrading Snapshot
- Day Range
- $4.07 – $4.21
- 52-Week Range
- $2.54 – $7.18
- Volume
- $2.13B
- Avg Volume
- $2.10B
- Shares Outstanding
- 163.8M
- Next Earnings
- Oct 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $133M
- Last Q Revenue
- $31M
- P/E Ratio
- -3.5
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.01
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +4.9%
Why Investors Own ANNX
- ✓High-growth profile — revenue up +2.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 64% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ANNEXON INC
ANNX
StockOtter · stockotter.spaceAbout ANNEXON INC
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Annexon: Preserving Patient Function Is The Real Investment Opportunity
Annexon targets functional patient outcomes in geographic atrophy and Guillain-Barré syndrome, aiming for clinical differentiation via vision and physical recovery preservation. ANNX maintains a cash runway into 2028, su
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes ARCHER II is the First Pivotal Trial Designed to Demon
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that i
Annexon to Participate in Upcoming September Investor Conferences
BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that i
Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript
Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript
Annexon Q2 Earnings Call Highlights
Annexon NASDAQ: ANNX said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study's existing 15-month primary endpoint. The c